StephenLiuMD(He/Him)

Oncology • Washington, DC

Thoracic Cancer

Associate Professor, Georgetown University School of Medicine

Join to view full profile

Dr. Liu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Liu's full profile

Already have an account?

Office
3800 Reservoir Rd NW
Lombardi Comprehensive Cancer Clinic
Washington, DC 20007
Phone+1 202-444-2223

Fax+1 202-444-7009

Summary

Dr. Stephen V. Liu, MD, is an Associate Professor of Medicine, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Lombardi Comprehensive Cancer Center of Georgetown University in Washington DC, USA. He is also the host for the official IASLC podcast, Lung Cancer Considered.

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2009 - 2010
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2008 - 2009
University of Pennsylvania Health SystemResidency, Internal Medicine, 2005 - 2008
University of Maryland School of MedicineClass of 2005

Certifications & Licensure

CA State Medical License 2008 - Present
MD State Medical License 2013 - 2026
DC State Medical License 2013 - 2024
PA State Medical License 2005 - 2008
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013

Clinical Trials

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor Start of enrollment: 2016 May 11
Active, not recruiting
Phase 1
A Study of EP0031 in Patients With Advanced RET-altered Malignancies Start of enrollment: 2022 Sep 30
Recruiting
Phase 1, Phase 2
Roles: Contact
A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) Start of enrollment: 2022 Jan 04
Recruiting
Phase 1, Phase 2

Publications & Presentations

PubMed

Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation.
David Hsiehchen, Andrew Elliott, Joanne Xiu, Andreas Seeber, Wafik El-Deiry
Cancer Cell. 2024-12-09
Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in No...
Alexander S Watson, Harris B Krause, Andrew Elliott, Alex Farrell, Stephen V Liu
Clinical Lung Cancer. 2024-12-01
Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors.
Dan Morgenstern-Kaplan, Samuel A Kareff, Asaad Trabolsi, Estelamari Rodriguez, Harris Krause
The Oncologist. 2024-11-04

Press Mentions

After "Astounding" Survival Results in SCLC, Updated Data Raise QuestionSeptember 17th, 2024
Second-Line Treatment Shortfall for Metastatic NSCLCJune 7th, 2024
Immunotherapy, Next-Generation Sequencing, and Shared Decision-Making in the Treatment of Non–Small Cell Lung CancerMay 17th, 2023
Join now to see all